Source comparison
MK-677 for Men 45-55 Andropause: Comparison
Before introducing any research protocol, men need clarity on how MK-677 compares to the alternatives they're already evaluating. Testosterone replacement therapy, peptide combinations, or direct GH injections. This table maps the practical trade-offs across m
This comparison does not assign a generated winner or score.
- Before introducing any research protocol, men need clarity on how MK-677 compares to the alternatives they're already evaluating. Testosterone replacement therapy, peptide combinations, or direct GH injections. This table maps the practical trade-offs across mechanism, administration burden, and hormonal impact.
- Primary Mechanism
- Ghrelin receptor agonist → endogenous GH secretion
- Exogenous testosterone → androgen receptor activation
- GHRH + GHSR agonism → pulsatile GH release
- Exogenous recombinant GH → direct IGF-1 elevation
- MK-677 preserves natural pulsatility without suppressing endogenous production. The only option that doesn't require post-cycle recovery.
- Administration Route
- Oral (once daily)
- Injection (weekly–biweekly) or transdermal gel (daily)
- Subcutaneous injection (1–2x daily)
- Subcutaneous injection (daily)
- Oral bioavailability (60%) eliminates injection site rotation, infection risk, and dosing complexity. The simplest protocol for long-term consistency.
- Hormonal Suppression Risk
- None. Amplifies natural axis
- Complete suppression of endogenous testosterone
- Minimal. May reduce over 6+ months
- Complete suppression of endogenous GH
- TRT and GH injections create dependency; stopping causes hypogonadism or rebound suppression. MK-677 and peptides can be cycled without lasting shutdown.
- Typical Dosing
- 12.5–25mg daily
- 100–200mg testosterone weekly
- CJC: 100–300mcg 2–3x/week; Ipamorelin: 200–300mcg 1–2x/daily
- 1–4 IU daily (0.33–1.33mg)
- MK-677 dosing is fixed and predictable; peptides require reconstitution, dose calculation, and refrigeration. Higher user error rate.
- IGF-1 Elevation
- 40–90% increase from baseline
- Minimal (indirect via aromatisation)
- 30–60% increase (dose-dependent)
- 100–300% increase (dose-dependent)
- MK-677 produces therapeutic IGF-1 elevation without the supra-physiological spikes that increase cancer marker concern with high-dose GH.
- Cost (Monthly)
- $80–120 for research-grade liquid or capsules
- $150–300 (depends on compounded vs brand)
- $200–400 (peptides + bacteriostatic water + syringes)
- $600–1,200 (pharmaceutical-grade GH)
- MK-677 offers 60% cost reduction vs peptides, 85% vs GH injections. Making it the most accessible long-term option for men self-funding research.